Administration of Almitrine
Phase 3Small molecule
Administration of Almitrine is one of 28 small molecule programs targeting COVID-19. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
309 competitors in COVID-19
#DrugCompanyPhaseTrials
1Administration of Almitrine
CCentre Hospitalier Universitaire de Nice
Phase 3
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Benadryl
PParkedale
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Virtual Reality1 trial
METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation (HYPNOLUX)
Recruiting·—·Phase 4·NCT05821517·150 enrolled
COVID-191 trial
Almitrine in COVID-19 Patients With ARDS Treated by HFNO
Completed·—··NCT05216575·62 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Administration of Almitrine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details